AlphAIAlphAI — Financial news for AI agents
finance.yahoo.comNOV 43 min read$MIRM

Mirum (MIRM) Q3 2026 Earnings Call Transcript

Mirum (MIRM) reported Q3 2026 net product sales of $186M, up from $133M last year. LIVMARLI drove growth with $133M in sales. The company raised full-year guidance to $715M-$720M. Mirum expects 5 potential regulatory submissions by 2027, including for volixibat, Brelovitug, and Atebrioz. The company also announced positive clinical trial results for its pipeline.

Original reporting
finance.yahoo.com
Published Nov 4, 2026, 3:29 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 4, 2026, 3:40 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Mirum (MIRM) Q3 2026 Earnings Call Transcript — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$MIRMBullishHigh
01

Why it matters

The earnings beat and guidance raise provide fresh material for traders; the data were not previously public.

02

Market read

First disclosure of Q3 results and guidance; material for price action.

03

What to watch

Execution risk on upcoming NDA submissions could temper upside.

Relevance 8/10Novelty 8/10Timing: post‑earnings release today

Background

Mirum (MIRM) presented its Q3 2026 earnings call, highlighting sales performance and pipeline progress.

Company-level read

Ticker impact

$MIRMBullishHigh confidence
Context

Q3 earnings call disclosed $186M sales and raised full-year guidance to $715‑720M, new data on pipeline.

Expected impact

likely upward pressure as market prices in higher revenue outlook

Evidence & confidence

First report of earnings and guidance; numbers are material for a mid‑cap biotech.

Market effects

Sector

Positive earnings may lift other rare‑disease biotech stocks.

Regional

U.S. biotech sector could see modest gains.

Global

Limited to biotech investors; no broad market effect.

Counterpoint

What could challenge this read

Guidance may be optimistic given pending regulatory risks.

Key entities

  • company
    Mirum

    Biotech firm focused on rare diseases.

Read at source← All news

StoryMirum Pharmaceuticals posts Q3 2026 results, FDA approval of Atebrioz and raises full‑year sales guidance

Also covered by

5 outlets

Related articles

NOV 4
$MIRMMed

H.C. Wainwright raises Mirum Pharmaceuticals price target to $202

H.C. Wainwright raised its price target on Mirum Pharmaceuticals (MIRM) to $202, citing strong Q3 2026 sales of $185.7M, up 40% YoY. LIVMARLI sales reached $133.4M, up 45% YoY. The company's revenue grew 44% over the last year with an 82% gross margin. Despite a wider-than-expected loss, other analysts also raised price targets, noting commercial strength and pipeline progress.

investing.com2 min
NOV 4
$MIRMMed

Citizens raises Mirum Pharmaceuticals price target on pipeline progress

Citizens raised its price target for Mirum Pharmaceuticals (MIRM) to $167 from $144, citing Livmarli's growth and a diversified pipeline. The company reported 44% revenue growth and 81.7% gross margin. Mirum's Q3 2026 revenue of $185.7M beat estimates, though it posted a wider-than-expected loss per share. The stock has a Strong Buy consensus with targets ranging from $118 to $200.

investing.com2 min
NOV 4
$MIRMMed

Mirum Pharmaceuticals Inc (MIRM) Q3 2026 Earnings Call Highlights: Raised Guidance

Mirum Pharmaceuticals (MIRM) raised its full-year guidance, citing broad-based growth, with adult PFIC as the biggest driver. Q3 saw elevated R&D expenses and minimal Takeda purchases of Livmarli. The company faces regulatory uncertainty for Belixabat and potential revenue headwinds. Management expects continued quarterly revenue growth of $10M-$15M through 2027, with key data readouts planned for Q1 2027.

finance.yahoo.com3 min
NOV 4
$MIRMHighAI 8/10

Mirum Pharmaceuticals Q3 Earnings Call Highlights

Mirum Pharmaceuticals reported Q3 revenue growth of $10M-$15M, expecting this trend to continue through 2027. ATEBRIOZ, approved in September, began U.S. launch with positive early feedback. The company anticipates multiple regulatory submissions in 2027. Mirum ended Q3 with $500M in cash and expects R&D expenses to decline to 10% of revenue long-term.

finance.yahoo.com3 min